172734-33-7

Basic information

• Product Name: 1-N-BOC-4-HYDROXY-4-PHENYLPIPERIDINE
• Synonyms: 1-BOC-4-PHENYL-4-HYDROXYPIPERIDINE;1-N-BOC-4-HYDROXY-4-PHENYLPIPERIDINE;tert-Butyl 4-hydroxy-4-phenylpiperidine-1-carboxylate;N-BOC-4-hydroxy-4-phenylpiperidine;4-Hydroxy-4-phenyl-1-tert-butoxycarbonylpiperidine
• CAS NO: 172734-33-7
• Molecular Formula: C₁₆H₂₃NO₃
• Molecular Weight: 277.362
• Mol File: 172734-33-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-N-BOC-4-HYDROXY-4-PHENYLPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-BOC-4-HYDROXY-4-PHENYLPIPERIDINE(172734-33-7)
• EPA Substance Registry System: 1-N-BOC-4-HYDROXY-4-PHENYLPIPERIDINE(172734-33-7)

Safety Data

• Hazardous Substances Data: 172734-33-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
1-N-BOC-4-HYDROXY-4-PHENYLPIPERIDINE is used as a building block for the synthesis of pharmaceutical compounds due to its versatile chemical structure and the presence of the BOC protecting group, which aids in the controlled formation of complex organic molecules.
Used in Organic Synthesis:
In the field of organic synthesis, 1-N-BOC-4-HYDROXY-4-PHENYLPIPERIDINE is utilized as an intermediate for the preparation of biologically active compounds. Its unique structure allows for further functionalization and modification to create a variety of organic molecules with potential applications.
Used in Research Chemicals:
1-N-BOC-4-HYDROXY-4-PHENYLPIPERIDINE is employed as an intermediate in the synthesis of research chemicals, contributing to the development of new compounds for scientific investigation and potential therapeutic applications.
Used in the Production of Complex Organic Molecules:
The BOC protecting group in 1-N-BOC-4-HYDROXY-4-PHENYLPIPERIDINE is used to control the reactivity of the nitrogen atom, making it a useful tool in the production of complex organic molecules. This feature is particularly valuable in the synthesis of compounds that require precise control over the reaction conditions and the introduction of functional groups.

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 167262-68-2 N-(t-butyloxycarbonyl)-4-phenylpiperidine-4-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 51304-58-6 4-cyano-4-phenylpiperidine hydrochloride 
• 158144-79-7 tert-butyl 4-cyano-4-phenylpiperidine-1-carboxylate 
• 158144-80-0 1-Boc-4-phenyl-4-piperidinecarbaldehyde 
• 40807-61-2 4-hydroxy-4-phenylpiperidin 
• 34619-03-9 tert-butyldicarbonate 
• 100-59-4 phenylmagnesium chloride 
• 5123-13-7 5,5-dimethyl-2-phenyl-1,3,2-dioxaborinane 
• 108-86-1 bromobenzene 
• 591-51-5 phenyllithium 
• 98-80-6 phenylboronic acid 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 

Downstream Products

• 186347-72-8 4-phenyl-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 201609-37-2 4-methoxy-4-phenylpiperidine-1-carboxylic acid tert-butyl ester 
• 1225652-73-2 1-tert-butoxycarbonyl-4-butoxy-4-phenylpiperidine 
• 939-23-1 p-phenylpyridine 
• 26274-35-1 2,4-diphenylpyridine 
• 400770-91-4 4‐fluoro‐4‐phenylpiperidine 
• 3109-12-4 4-(4-hydroxy-4-phenyl-1-piperidinyl)-1-(4-fluorophenyl)-1-butanone 
• 123387-49-5 tert-butyl 4-phenylpiperidine-1-carboxylate 
• 83949-38-6 4-methoxy-4-phenylpiperidine hydrochloride 
• 1266656-79-4 N-(1-(4,4-bis(4-fluorophenyl)butyl)-4-phenylpiperidin-4-yl)acetamide 
• 1266656-74-9 1-(4,4-bis(4-fluorophenyl)butyl)-4-phenylpiperidin-4-yl acetate 
• 31633-81-5 1-[4,4-Bis-(4-fluoro-phenyl)-butyl]-4-phenyl-piperidin-4-ol 
• 201609-38-3 4‐methoxy‐4‐phenylpiperidine 
• 40807-61-2 4-hydroxy-4-phenylpiperidin 

Relevant articles and documents

NHC-coordinated palladacycle catalyzed 1,2-addition of arylboronates to unactivated ketones

Palladium catalyzed intermolecular 1,2-addition of arylboronate to unactivated ketone was investigated. NHC-coordinated palladacycle 4c exhibited catalytic activity for the reactions and provided the corresponding tertiary alcohols and γ,γ-disubstituted γ-lactones in good to excellent yields.

COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS

The present invention generally relates to compounds that are useful for inhibiting one or more trypsin-like S1 serine proteases, HGFA, matriptase, hepsin, KLK5 and/or TMPRSS2 as well as cysteine proteases including trypsin-like cysteine proteases (e.g. C

Bulky N-Heterocyclic-Carbene-Coordinated Palladium Catalysts for 1,2-Addition of Arylboron Compounds to Carbonyl Compounds

The synthesis of primary, secondary, and tertiary alcohols by the 1,2-addition of arylboronic acids or boronates to carbonyl compounds, including unactivated ketones, using novel bulky yet flexible N-heterocyclic carbene (NHC)-coordinated 2,6-di(pentan-3-yl)aniline (IPent)-based cyclometallated palladium complexes (CYPs) as catalysts is reported. The PhS-IPent-CYP-catalyzed reactions are efficient at low catalyst loadings (0.02–0.3 mol% Pd), and the exceptional catalytic activity for 1,2-addition is attributed to the steric bulk of the NHC ligand. These reactions can yield a wide range of functionalized benzylic alcohols that are difficult to synthesize by classical protocols using highly active organomagnesium or lithium reagents.

Propafenone analogue with additional H-bond acceptor group shows increased inhibitory activity on P-glycoprotein

P-glycoprotein (P-gp) is an ATP-dependent efflux pump that has a marked impact on the absorption, distribution, and excretion of therapeutic drugs. As P-gp inhibition can result in drug–drug interactions and altered drug bioavailability, identifying molec

Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin

Matriptase and hepsin are type II transmembrane serine proteases (TTSPs). Along with related S1 trypsin like serine protease HGFA (hepatocyte growth factor activator), their unregulated proteolytic activity has been associated with cancer including tumor progression and metastasis. These three proteases have two substrates in common, hepatocyte growth factor (HGF) and macrophage stimulating protein (MSP), the ligands for MET and recepteur d'origine nantais (RON) receptor tyrosine kinases. Mechanism-based tetrapeptide and benzamidine inhibitors of these proteases have been shown to block HGF/MET and MSP/RON cancer cell signaling. Herein, we have rationally designed a new class of peptidomimetic hybrid small molecule piperidine carbamate dipeptide inhibitors comparable in potency to much larger tetrapeptides. We have identified multiple compounds which have potent activity against matriptase and hepsin and with excellent selectivity over the off-target serine proteases factor Xa and thrombin.

Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor

Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D2R, whereas clozapine exhibits relatively slow association/fast dissociation. Recently, we have provided evidence that slow dissociation from the D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side effects independent of its D2R action. Our results suggest an optimal kinetic profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted a structure-kinetic relationship study of haloperidol and revealed that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of these kinetic parameters may allow development of novel APDs based on the haloperidol scaffold with improved side-effect profiles.

Modulators of protease activated receptors

The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as metabolic syndrome, obesity, type II diabetes, fibrosis and cardiovascular diseases, whether they are used alone or in combination with other treatment modalities.

NOVEL BETULINIC SUBSTITUTED AMIDE DERIVATIVES AS HIV INHIBITORS

The present invention relates to novel betulinic substituted amide compounds of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y, Z1, Z2, Z3 and are Formula (II) as defined herein. The invention novel betulinic substituted amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.

HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS

Inhibitors of sepiapterin reductase of formula (I) or (I'), wherein the substituents are defined as in the claims, and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.

The use of organolithium reagents for the synthesis of 4-aryl-2-phenylpyridines and their corresponding iridium(III) complexes

A versatile palladium-free route for the synthesis of 4-aryl-substituted phenylpyridines (ppy), starting from tert-butyl 4-oxopiperidine-1-carboxylate, is reported. Reaction with an aryllithium, followed by trifluoroacetic acid dehydration/deprotection and oxidation with 2-iodoylbenzoic acid and finally phenylation, gave 4 ligands (L1-4H): 2,4-diphenylpyridine, 4-(4-methoxyphenyl)-2-phenylpyridine, 2-phenyl-4-(o-tolyl)pyridine and 4-mesityl-2-phenylpyridine. These ligands were coordinated to iridium to give the corresponding Ir(L)2(A) complexes (Ir1-7), where A = ancillary ligand acetylacetate or 2-picolinate. This was used to demonstrate that, through a combination of ancillary ligand choice and torsional twisting between the 4-aryl substituents of the ppy ligands, it is possible to tune the phosphorescent emission of the complexes in the range 502-560 nm.